
Opinion|Videos|November 8, 2024
Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches
Key Takeaways
- mCSPC treatment requires personalized approaches, considering disease burden, patient comorbidities, and genetic profiles to optimize outcomes.
- There is a significant need for more effective therapeutic strategies to improve patient outcomes in mCSPC.
Panelists discuss how some of the most critical challenges and unmet needs in the treatment and management of metastatic castration-sensitive prostate cancer (mCSPC) include the effectiveness of monotherapy, the need for better risk stratification, and the integration of novel therapies to improve patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What are some of the most critical challenges and unmet needs in the treatment and management of mCSPC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
4
Microbial dysbiosis may predict response to CBM588 in mRCC
5







